Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Buy” from Brokerages
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating […]
